Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Expert Rev Anticancer Ther. 2018 Sep;18(9):823–836. doi: 10.1080/14737140.2018.1503954

Figure 3. Recommended phase II dose of apalutamide.

Figure 3

FDHT-PET imaging data from 16 patients in the phase I study support 240 mg as the optimal dose of apalutamide.

FDHT: [18F]fluoro-5α-dihydrotestosterone; PET: positron emission tomography; SUVmax–avg: standard uptake value (maximum–average).

Source: Rathkopf et al., 2013[39] (with permission). Reprinted with permission. © (2013) American Society of Clinical Oncology. All rights reserved.